Aardvark Therapeutics, Inc. Common Stock (AARD) NASDAQ

13.80

+0.285(+2.11%)

Updated at July 01 12:12PM

Currency In NaN

Previous Close13.52
Open14.28
Day High14.28
Day Low13.28
52-Week High19.58
52-Week Low4.88
Volume8,623
Average Volume77,988
Market Cap299.4M
PE-10.78
EPS-1.28
Moving Average 50 Days10.88
Moving Average 200 Days10.62
Change0.28

Related News

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

GlobeNewswire Inc.

SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

GlobeNewswire Inc.

Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SAN DIEGO, Ma

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

GlobeNewswire Inc.

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the t